Адам организміндегі нәрсе өсу факторы

Mammalian protein found in Homo sapiens

Nerve growth factor (NGF) is a neurotrophic factor and neuropeptide primarily involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It is perhaps the prototypical growth factor, in that it was one of the first to be described. Since it was first isolated by Nobel Laureates Rita Levi Montalcini and Stanley Cohen in 1956, numerous biological processes involving NGF have been identified, two of them being the survival of pancreatic beta cells and the regulation of the immune system.

NGF is initially in a 7S, 130 kDa complex of 3 proteins – Alpha NGF, Beta NGF, and Gamma NGF (2:1:2 ratio) when expressed. This form of NGF is also referred to as proNGF (NGF precursor). The gamma subunit of this complex acts as a serine protease, and cleaves the N terminal of the beta subunit, thereby activating the protein into functional NGF. The term nerve growth factor usually refers to the 2.5S, 26 kDa beta subunit of the protein, the only component of the 7S NGF complex that is biologically active (i. e. acting as a signaling molecule).

As its name suggests, NGF is involved primarily in the growth, as well as the maintenance, proliferation, and survival of nerve cells (neurons) and is critical for the survival and maintenance of sympathetic and sensory neurons as they undergo apoptosis in its absence. However, several recent studies suggest that NGF is also involved in pathways besides those regulating the life cycle of neurons.

NGF can drive the expression of genes such as bcl 2 by binding to the Tropomyosin receptor kinase A, which stimulates the proliferation and survival of the target neuron. High affinity binding between proNGF, sortilin, and p75NTR can result in either survival or programmed cell death. Study results indicate that superior cervical ganglia neurons that express both p75NTR and TrkA die when treated with proNGF, while NGF treatment of these same neurons results in survival and axonal growth. Survival and PCD mechanisms are mediated through adaptor protein binding to the death domain of the p75NTR cytoplasmic tail. Survival occurs when recruited cytoplasmic adaptor proteins facilitate signal transduction through tumor necrosis factor receptor members such as TRAF6, which results in the release of nuclear factor κB (NF κB) transcription activator.

NGF plays a critical role in the regulation of both innate and acquired immunity. In the process of inflammation, NGF is released in high concentrations by mast cells, and induces axonal outgrowth in nearby nociceptive neurons. This leads to increased pain perception in areas under inflammation. In acquired immunity, NGF is produced by the Thymus as well as CD4+ T cell clones, inducing a cascade of maturation of T cells under infection.

NGF is abundant in seminal plasma. Recent studies have found that it induces ovulation in some mammals e. g. "induced" ovulators, such as llamas. Surprisingly, research showed that these induced animals will also ovulate when semen from on schedule or "spontaneous" ovulators, such as cattle is used. Its significance in humans is unknown. It was previously dubbed ovulation inducing factor (OIF) in semen before it was identified as beta NGF in 2012.

NGF binds with at least two classes of receptors: the tropomyosin receptor kinase A (TrkA) and low affinity NGF receptor (LNGFR/p75NTR). Both are associated with neurodegenerative disorders. When NGF binds to the TrkA receptor, it drives the homodimerization of the receptor, which in turn causes the autophosphorylation of the tyrosine kinase segment. Once bound, the complex undergoes endocytosis and activates the NGF transcriptional program, following two major pathways, the Ras/MAPK pathway and the PI3K/Akt pathway. The binding of NGF to TrkA also leads to the activation of PI 3 kinase, ras, and PLC signaling pathways. Alternatively, the p75NTR receptor can form a heterodimer with TrkA, which has higher affinity and specificity for NGF. Studies suggest that NGF circulates throughout the entire body via the blood plasma, and is important for the overall maintenance of homeostasis.

Binding interaction between NGF and the TrkA receptor facilitates receptor dimerization and tyrosine residue phosphorylation of the cytoplasmic tail by adjacent Trk receptors. Trk receptor phosphorylation sites operate as Shc adaptor protein docking sites, which undergo phosphorylation by the TrkA receptor Once the cytoplasmic adaptor protein (Shc) is phosphorylated by the receptor cytoplasmic tail, cell survival is initiated through several intracellular pathways. One major pathway leads to the activation of the serine/threonine kinase, Akt. This pathway begins with the Trk receptor complex recruitment of a second adaptor protein called growth factor receptor bound protein 2 (Grb2) along with a docking protein called Grb2 associated Binder 1 (GAB1). However, if either kinase is constitutively active, neurons survive even without NGF. became the definitive proof for the existence of the protein. Levi Montalcini later remarked:The tumor had given a first hint of its existence in St. Louis but it was in Rio de Janeiro that it revealed itself, and it did so in a theatrical and grand way, as if spurred by the bright atmosphere of that explosive and exhuberant manifestation of life that is the Carnival in Rio. However, its discovery, along with the discovery of other neurotrophins, was not widely recognized until 1986, when it won the Nobel Prize in Physiology or Medicine. Studies in 1971 determined the primary structure of NGF. This eventually led to the discovery of the NGF gene. NGF is abundant in seminal plasma. Recent studies have found that it induces ovulation in some mammals. Nerve Growth Factors (NGF) were initially discovered due to their actions during development, but NGF are now known to be involved in the function throughout the life of the animal.

Nerve growth factor has been shown to interact with Tropomyosin receptor kinase A.

NGF, specifically mouse (murine) nerve growth factor, has been available as a licensed medicine in China since 2003. There is evidence of improved patient outcomes for several diseases of the nervous system, including acute intracerebral hemorrhage, global developmental delay, optic atrophy, epilepsy and cerebral palsy. This is significant as there are few medicines which can treat injuries and diseases of the nervous system. Research and clinical use outside of China is limited despite a large body of evidence supporting its use.